IT 1208

Drug Profile

IT 1208

Alternative Names: IT-1208

Latest Information Update: 27 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko Kirin
  • Developer IDAC Theranostics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Research HIV infections

Most Recent Events

  • 24 Mar 2017 Phase-I clinical trials in Cancer (Late-stage disease, Metastatic disease) in Japan (Parenteral) (UMIN000026564)
  • 17 May 2016 IT 1208 will be licensed to ONO Pharmaceuticals to Ono Pharmacaceuticals signs a definitive agreement with IDAC Theranostics for the licensure of IT 1208
  • 17 May 2016 IDAC Theranostic plans a phase X trial for Cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top